Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus fruquintinib versus fruquintinib alone in colorectal cancer with unresectable liver metastases after second-line chemotherapy failure
ChiCTR2100051415Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fruquintinib, fluorouracil, oxaliplatin and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective disease response rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
fruquintinibfluorouraciloxaliplatinfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100051415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051415.